Delving into the Latest Updates on HER2 targeted ADC(Araris) with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms-

Target

HER2

Mechanism

HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)

Therapeutic Areas

Neoplasms

Active Indication

Solid tumor

Inactive Indication-

Originator Organization

Araris Biotech AGStartup

Active Organization

Araris Biotech AGStartup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Antibody-drug conjugates(ADCs)have become widely used in the treatment of various malignancies over the past 15 years. In breast cancer, T-DM1 and T-DXd which is HER2-targeted ADC have been approved and are broadly used in Japan. Sacituzumab govitecan, TROP2-ADC has been approved in US. Hence, multiple ADCs could be used for breast cancer treatment. In gynecological cancers, tisotumab vedotin for cervical cancer and mirvetuximab soravtansine for ovarian cancer have been approved in the US. Optimizing treatment sequences and overcoming resistance mechanisms for ADC are important challenges in the situations where multiple ADCs are available. The current development landscape suggests further enhancement of ADC treatment efficacy through new targets, novel payloads, bispecific ADCs, and combination therapies with immunotherapy. This article outlines the current status of ADCs in breast and gynecological cancers, highlighting ongoing development and challenges emerging in the field.

100 Deals associated with HER2 targeted ADC(Araris)

Login to view more data